Modulation of proteasome activity by curcumin and didemethylcurcumin

Area of Science:

• Biochemistry
• Pharmacology
• Molecular Biology

Background:

• Proteasome function is a key target for cancer and neurodegenerative disease therapies.
• Curcumin, a natural polyphenol, exhibits diverse biological activities, including potential proteasome inhibition.
• Understanding curcumin's precise interaction with the proteasome is crucial for therapeutic development.

Purpose of the Study:

• To investigate the dose-dependent modulation of proteasome activity by curcumin and its synthetic derivative, didemethylcurcumin (CUIII).
• To compare the efficacy of curcumin and CUIII in altering proteasome function.
• To elucidate the binding interactions between these compounds and the 20S proteasome using molecular docking.

Main Methods:

• In vitro cell culture assays to measure proteasome activity.
• Molecular docking simulations to analyze binding affinities and interactions with the 20S proteasome catalytic subunit.
• Comparative analysis of curcumin and didemethylcurcumin (CUIII) effects at various concentrations.

Main Results:

• Both curcumin and CUIII exhibited biphasic modulation of proteasome activity: activation at nanomolar concentrations and inhibition at micromolar concentrations.
• Curcumin demonstrated greater efficacy than CUIII in both enhancing and inhibiting proteasome activity.
• Molecular docking revealed stronger binding affinity (lower Kd) for curcumin (0.0054 µM) compared to CUIII (1.3167 µM) with the 20S proteasome.

Conclusions:

• Curcumin and its didemethyl derivative are effective modulators of proteasome activity in a dose-dependent manner.
• Curcumin's superior efficacy suggests it may be a more potent therapeutic agent than CUIII.
• These findings support the potential utility of curcumin and its derivatives in treating diseases associated with proteasome dysfunction, such as cancer and neurodegeneration.